The GLP-1 based therapies were also not associated with a significant change in adiponectin levels in the blood with a mean difference in percent change from baseline between GLP-1 based therapies and controls of 53.63 [133.86, 26.61] % (P = 0.19
Studies have demonstrated that GLP-1 receptor activation may reduce production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1) the same inflammatory mediators that drive joint destruction in rheumatoid arthritis
Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, et al
Some companies sell oral peptide "supplements"these are generally not effective for the same reasons
Additionally, Klinic provides financial assistance programs and other payment options to guarantee sustained access to this groundbreaking treatment